GRIFOLS S A/S (NASDAQ:GRFS) Shares Gap Up to $19.85

Shares of GRIFOLS S A/S (NASDAQ:GRFS) gapped up before the market opened on Wednesday . The stock had previously closed at $19.39, but opened at $19.85. GRIFOLS S A/S shares last traded at $20.44, with a volume of 2,336,598 shares traded.

Several equities research analysts have recently issued reports on GRFS shares. Zacks Investment Research raised shares of GRIFOLS S A/S from a “sell” rating to a “hold” rating in a research report on Monday. ValuEngine downgraded shares of GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. raised shares of GRIFOLS S A/S from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $21.00 to $22.50 in a research report on Thursday, June 27th. Finally, BidaskClub downgraded shares of GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research report on Wednesday. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $20.75.

The company’s fifty day moving average is $21.46 and its 200 day moving average is $20.11. The firm has a market cap of $13.65 billion, a price-to-earnings ratio of 17.53, a PEG ratio of 1.26 and a beta of 1.11. The company has a quick ratio of 0.95, a current ratio of 2.68 and a debt-to-equity ratio of 1.38.

GRIFOLS S A/S (NASDAQ:GRFS) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $0.33 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.33. GRIFOLS S A/S had a net margin of 11.82% and a return on equity of 14.88%. The business had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.38 billion. On average, equities research analysts forecast that GRIFOLS S A/S will post 1.23 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. AKO Capital LLP boosted its holdings in GRIFOLS S A/S by 5.5% during the second quarter. AKO Capital LLP now owns 12,562,923 shares of the biotechnology company’s stock worth $265,078,000 after purchasing an additional 654,497 shares during the last quarter. FIL Ltd lifted its stake in GRIFOLS S A/S by 12.2% in the first quarter. FIL Ltd now owns 8,170,942 shares of the biotechnology company’s stock valued at $164,318,000 after acquiring an additional 887,474 shares during the last quarter. First Trust Advisors LP raised its position in shares of GRIFOLS S A/S by 9.7% in the first quarter. First Trust Advisors LP now owns 5,125,719 shares of the biotechnology company’s stock valued at $103,078,000 after purchasing an additional 453,032 shares during the period. Farallon Capital Management LLC raised its position in shares of GRIFOLS S A/S by 5.3% in the second quarter. Farallon Capital Management LLC now owns 3,080,083 shares of the biotechnology company’s stock valued at $64,990,000 after purchasing an additional 153,731 shares during the period. Finally, Morgan Stanley raised its position in shares of GRIFOLS S A/S by 65.2% in the second quarter. Morgan Stanley now owns 1,827,582 shares of the biotechnology company’s stock valued at $38,562,000 after purchasing an additional 721,604 shares during the period. Institutional investors and hedge funds own 17.91% of the company’s stock.

GRIFOLS S A/S Company Profile (NASDAQ:GRFS)

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Featured Story: Why do corrections happen?

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.